JP7868861B2 - 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法 - Google Patents

線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法

Info

Publication number
JP7868861B2
JP7868861B2 JP2023556985A JP2023556985A JP7868861B2 JP 7868861 B2 JP7868861 B2 JP 7868861B2 JP 2023556985 A JP2023556985 A JP 2023556985A JP 2023556985 A JP2023556985 A JP 2023556985A JP 7868861 B2 JP7868861 B2 JP 7868861B2
Authority
JP
Japan
Prior art keywords
compound
fap
group
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023556985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510267A (ja
JP2024510267A5 (enExample
Inventor
ロウ，フィリップ，スチュワート
ムッカマラ，ラメシュ
スリニヴァサラオ，マッドゥリ
リンデマン，スペンサー，ディー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2024510267A publication Critical patent/JP2024510267A/ja
Publication of JP2024510267A5 publication Critical patent/JP2024510267A5/ja
Application granted granted Critical
Publication of JP7868861B2 publication Critical patent/JP7868861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023556985A 2021-03-16 2022-03-12 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法 Active JP7868861B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202163200592P 2021-03-16 2021-03-16
US202163200593P 2021-03-16 2021-03-16
US202163161835P 2021-03-16 2021-03-16
US63/200,592 2021-03-16
US63/161,835 2021-03-16
US63/200,593 2021-03-16
US202163165583P 2021-03-24 2021-03-24
US202163165563P 2021-03-24 2021-03-24
US202163165550P 2021-03-24 2021-03-24
US63/165,550 2021-03-24
US63/165,563 2021-03-24
US63/165,583 2021-03-24
PCT/US2022/020084 WO2022197567A1 (en) 2021-03-16 2022-03-12 Compounds targeting fibroblast-activation protein and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024510267A JP2024510267A (ja) 2024-03-06
JP2024510267A5 JP2024510267A5 (enExample) 2025-03-21
JP7868861B2 true JP7868861B2 (ja) 2026-06-02

Family

ID=83320754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556985A Active JP7868861B2 (ja) 2021-03-16 2022-03-12 線維芽細胞活性化タンパク質を標的とする化合物、およびその使用方法

Country Status (6)

Country Link
US (1) US20240238458A1 (enExample)
EP (1) EP4308110A4 (enExample)
JP (1) JP7868861B2 (enExample)
CA (1) CA3212210A1 (enExample)
TW (1) TW202300143A (enExample)
WO (1) WO2022197567A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230405153A1 (en) * 2022-06-17 2023-12-21 Purdue Research Foundation Fibroblast activation protein-targeted magnetic resonance imaging agents, compositions, and methods of use
TWI879182B (zh) * 2023-10-26 2025-04-01 國家原子能科技研究院 白蛋白雙重結合功能之纖維母細胞活化蛋白化合物或其鹽
WO2025155818A1 (en) * 2024-01-19 2025-07-24 Purdue Research Foundation Fibroblast activation protein-targeted radioligands with pharmacokinetic modulators
WO2025171343A1 (en) * 2024-02-08 2025-08-14 Immunome, Inc. Compounds targeting fibroblast-activation protein and methods of use thereof
CN118593732B (zh) * 2024-06-27 2025-03-11 华中科技大学同济医学院附属同济医院 一种心肌炎核素分子探针及其制备方法和应用
WO2026156254A1 (en) * 2025-01-17 2026-07-23 Immunome, Inc. Compounds targeting fibroblast-activation protein and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
WO2019190266A1 (ko) 2018-03-30 2019-10-03 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
JP2020502130A (ja) 2016-12-14 2020-01-23 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2020081522A1 (en) 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
WO2020205948A1 (en) 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2021016392A1 (en) 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606785A1 (en) * 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
IL325256A (en) * 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234431A1 (en) 2009-03-13 2010-09-16 National Health Research Institutes Pyrrolidine compounds
JP2020502130A (ja) 2016-12-14 2020-01-23 パーデュー・リサーチ・ファウンデイションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2019190266A1 (ko) 2018-03-30 2019-10-03 (주)퓨쳐켐 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품
WO2020081522A1 (en) 2018-10-17 2020-04-23 Purdue Research Foundation Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis
WO2020205948A1 (en) 2019-04-03 2020-10-08 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
WO2021016392A1 (en) 2019-07-22 2021-01-28 Purdue Research Foundation Multivalent fibroblast-targeted agents and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tsai, Ting-Yueh 他，Substituted 4-Carboxymethylpyroglutamic Acid Diamides as Potent and Selective Inhibitors of Fibroblast Activation Protein，Journal of Medicinal Chemistry，2010年，53(18)，6572-6583

Also Published As

Publication number Publication date
JP2024510267A (ja) 2024-03-06
TW202300143A (zh) 2023-01-01
EP4308110A4 (en) 2025-06-18
EP4308110A1 (en) 2024-01-24
CA3212210A1 (en) 2022-09-22
WO2022197567A1 (en) 2022-09-22
US20240238458A1 (en) 2024-07-18

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260514

R150 Certificate of patent or registration of utility model

Ref document number: 7868861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150